Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study
C. Schilder(Radboud University Nijmegen), Sanne B. Schagen(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Willem Boogerd(The Netherlands Cancer Institute), Caroline Seynaeve(Radboud University Nijmegen), L.V.A.M. Beex, F. S. van Dam(Radboud University Nijmegen), Petronella C. Eggens(The Netherlands Cancer Institute), Chad M. Gundy(Radboud University Nijmegen), Sabine C. Linn(Oncode Institute)
Cited by 119
Related Papers
Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition
|New England Journal of Medicine|2004|1.7k
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
|The Lancet Oncology|2007|278
Effects of Tamoxifen and Exemestane on Cognitive Functioning of Postmenopausal Patients With Breast Cancer: Results From the Neuropsychological Side Study of the Tamoxifen and Exemestane Adjuvant Multinational Trial
|Journal of Clinical Oncology|2010|264
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer
|New England Journal of Medicine|2003|262